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Reply to Classification of biliary
tract cancer (BTC): evaluation of
all entities
We thank Tonini et al. for their interest in our work and agree
that various subsites of biliary tract cancer (BTC) may have
different risk factors, treatment approaches and prognosis [1].
However, in the International Classification of Diseases (ICD)
9th [2] and 10th [3] Revisions, neoplasms arising from
intrahepatic ducts are classified within liver cancers (C22,
Malignant neoplasm of liver and intrahepatic bile ducts in
the ICD-10th Revision) and not biliary tract neoplasms (C23,
C24 in the ICD-10th Revision). The scope for misclassification
of intrahepatic duct neoplasm with primary and metastatic liver
cancer is therefore unquantified but potentially substantial [4, 5].
More important, on the basis of national death certification,
no distinction is possible also within various subtypes of
extrahepatic BTCs. Data from several cancer registration areas
worldwide are more valid and accurate [6, 7], and some
distinction is possible on incidence data between extrahepatic
bile ducts, gall-bladder and ampulla of Vater. We added
therefore a figure to our recent work [7] showing the
distribution across subsites in selected cancer registries. Apart
from a few areas from India, Japan, China and Korea, most
neoplasms arise from the gall-bladder, particularly in high-
incidence areas. The reader should, however, also consider the
variable proportion of unspecified subsites in different registries.
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